ASH 2024: Global Updates in the Management of Chronic Lymphocytic Leukemia

Dr Niemann provides an overview of the evolving treatment landscape of CLL.

A panel of medical experts continues their discussion surrounding an array of treatment options for CLL.

A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.

Panelists discuss, role of time-limited therapy with venetoclax-obi in this setting, highlighting the underlying rationale and data supporting this approach.

Panelists discuss, which patients are favored for the Venetoclax-Obinutuzumab treatment approach.

Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.

Panelists discuss the role of ven-ibr in patient populations.

Panelists review recent ESMO guideline updates for the frontline management of patients with CLL and a TP53 or del(17p) mutation.

Panelists discuss the ongoing trials evaluating other BCL2i/BTKi combination approaches.

Panelists review recent ESMO guideline updates for managing early relapse after venetoclax-based time-limited therapy, managing relapse after chemoimmunotherapy or late relapse after venetoclax-based time-limited therapy and defining early versus late relapse.

Panelists comment on the role of combination venetoclax-ibrutinib in this setting and available supporting data.

Panelists discuss the role of non-covalent BTKis in this setting and available supporting data (high level).

Panelists comment on the increasing preference for fixed-duration therapy over treatment until progression, as reflected in recent guideline updates.